Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

QR Code

Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

Xiao-yu Liang,1 Fen-Fang Hong,2 Shu-Long Yang1 1Department of Physiology, College of Medicine, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Experimental Teaching Center, Nanchang University, Nanchang, 330031, People’s Republic of ChinaCorrespondence: Shu-Lo...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Liang XY, Hong Ff, Yang SL
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	astragaloside iv non-alcoholic fatty liver disease lipid accumulation oxidative stress apoptosis. Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/9c04d24d1f844b5e9681e2b6a9c1f542
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Astragaloside IV Inhibits Mitochondrial-Dependent Apoptosis of the Dorsal Root Ganglion in Diabetic Peripheral Neuropathy Rats Through Modulation of the SIRT1/p53 Signaling Pathway
par: Ben Y, et autres
Publié: (2021)

Current concepts of the pathogenesis of non-alcoholic fatty liver disease
par: Evgenia Pavlovna Kosobyan, et autres
Publié: (2010)

Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury
par: Xianhui Kang, et autres
Publié: (2021)

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
par: Haoran Jing, et autres
Publié: (2021)

Body Mass Index and Indicators of Lipid Exchange in Liver Steatosis of Alcoholic and Nonalcoholic Genesis in Residents of Rural Area: Similarities and Differences
par: N. V. Mikhaylova, et autres
Publié: (2019)

Non-Alcoholic Fatty Liver Disease and Hypothyroidism: Review of Clinical and Experimental Studies
par: Tetiana Ranhulova
Publié: (2021)

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
par: Pegah Golabi, et autres
Publié: (2022)

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
par: Hao Xu, et autres
Publié: (2021)

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
par: Satoru Hagiwara, et autres
Publié: (2021)

Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
par: Ramesh B. Kasetti, et autres
Publié: (2021)

Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
par: Aleksandr I. Pavlov, et autres
Publié: (2021)

Non-Alcoholic Fatty Liver Disease as a Risk for Colorectal Cancer Development and the Role of Screening Colonoscopy in Clinical Practice
par: Cosmas Rinaldi Adithya Lesmana, et autres
Publié: (2019)

Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies
par: Aleksandr E. Nosov, et autres
Publié: (2021)

Astragaloside IV Protects from PM2.5-Induced Lung Injury by Regulating Autophagy via Inhibition of PI3K/Akt/mTOR Signaling in vivo and in vitro
par: Pei C, et autres
Publié: (2021)

(+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα–FGF21 Pathway
par: Yiyuan Xi, et autres
Publié: (2021)

Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice
par: Jian-Lin Lai, et autres
Publié: (2021)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
par: Siyu Yu, et autres
Publié: (2021)

Adiponutrin and Adiponectin Gene Variants in Indonesian Patients with Non-Alcoholic Fatty Liver Disease: a Preliminary Study
par: Rayvita AN Meagratia, et autres
Publié: (2021)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
par: Lauszus JS, et autres
Publié: (2021)

Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways
par: Tahmina Yasmin, et autres
Publié: (2021)

Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease
par: Stanislav Kotlyarov, et autres
Publié: (2021)

Obesity and nonalcoholic fatty liver disease: current perspectives
par: Sarwar R, et autres
Publié: (2018)

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
par: Gharaibeh NE, et autres
Publié: (2019)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
par: Daniela Maria Tanase, et autres
Publié: (2021)

Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease
par: Xiaojiaoyang Li, et autres
Publié: (2021)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
par: Tingfeng Wu, et autres
Publié: (2021)

Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry
par: Alswat K, et autres
Publié: (2021)

PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS OF UNCONTROLLED AND CONTROLLED TYPE 2 DIABETES MELLITUS
par: Aqeela Rashid, et autres
Publié: (2019)

Non-invasive Diagnostics of Liver Fibrosis
par: Mihaylov R., et autres
Publié: (2017)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
par: Sue Shea, et autres
Publié: (2021)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
par: Chen L, et autres
Publié: (2020)

Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease
par: Ruiwen Wang, et autres
Publié: (2021)

Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease
par: José Ignacio Martínez-Montoro, et autres
Publié: (2021)

Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians
par: Mahamid M, et autres
Publié: (2018)

Total polyunsaturated fatty acid intake and the risk of non-alcoholic fatty liver disease in Chinese Han adults: a secondary analysis based on a case–control study
par: Yong Xie, et autres
Publié: (2021)

High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes
par: Tan Y, et autres
Publié: (2021)

Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
par: Gwyneth Shook Ting Soon, et autres
Publié: (2021)

Astragalus Polysaccharides and Saponins Alleviate Liver Injury and Regulate Gut Microbiota in Alcohol Liver Disease Mice
par: Jingxuan Zhou, et autres
Publié: (2021)

Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach
par: Ivica Grgurevic, et autres
Publié: (2021)

Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
par: Fatemeh Naeini, et autres
Publié: (2021)